Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0GD4Q
|
|||
| Drug Name |
Patidegib
|
|||
| Synonyms |
Patidegib hydrochloride; UNII-ZL14FCA5PK; 1169829-40-6; ZL14FCA5PK; IPI-926 Hydrochloride; Saridegib HCl; Patidegib [USAN:INN]; Saridegib [Rescinded USAN]; Saridegib hydrochloride (USAN); CHEMBL2105764; D10325; Methanesulfonamide, N-((2S,3R,3'R,3aS,4'aR,6S,6'aR,6'bS,7aR,12'aS,12'bS)- 2',3',3a,4,4',4'a,5,5',6,6',6'a,6'b,7,7',7a,8',10',12',12'a,12'b-eicosahydro-3,6,11',12'b-tetramethylspiro(furo(3,2-b)pyridine-2(3H),9'(1'H)-naphth(2,1-a)azulen)-3'-yl)-
Click to Show/Hide
|
|||
| Indication | Basal cell carcinoma [ICD-11: 2C32; ICD-10: C44] | Phase 2 | [1] | |
| Basal cell nevus syndrome [ICD-11: 2C32; ICD-10: C44] | Phase 2 | [2] | ||
| Chondrosarcoma [ICD-11: 2B50; ICD-9: 170.9] | Discontinued in Phase 2 | [3], [4] | ||
| Company |
PellePharm San Francisco, CA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H48N2O3S
|
|||
| Canonical SMILES |
CC1CC2C(C(C3(O2)CCC4C5CCC6CC(CCC6(C5CC4=C(C3)C)C)NS(=O)(=O)C)C)NC1
|
|||
| InChI |
1S/C29H48N2O3S/c1-17-12-26-27(30-16-17)19(3)29(34-26)11-9-22-23-7-6-20-13-21(31-35(5,32)33)8-10-28(20,4)25(23)14-24(22)18(2)15-29/h17,19-23,25-27,30-31H,6-16H2,1-5H3/t17-,19+,20+,21+,22-,23-,25-,26+,27-,28-,29-/m0/s1
|
|||
| InChIKey |
HZLFFNCLTRVYJG-WWGOJCOQSA-N
|
|||
| CAS Number |
CAS 1037210-93-7
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hedgehog signaling pathway (HS pathway) | Target Info | Inhibitor | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8198). | |||
| REF 4 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029135) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.